Passive Protection Assay of Monoclonal Antibodies Against Dengue Virus in Suckling Mice

被引:0
|
作者
Zongtao Chen
Li-Mei Liu
Na Gao
Xiao-Feng Xu
Jun-Lei Zhang
Jia-Li Wang
Jing An
机构
[1] Third Military Medical University,Department of Microbiology
[2] Third Military Medical University,Institute of Pathology, Southwest Hospital
[3] Capital Medical University,Department of Microbiology School of Basic Medical Sciences
来源
Current Microbiology | 2009年 / 58卷
关键词
Dengue Virus; Dengue Hemorrhagic Fever; Plaque Form Unit; Line 8F12; Dengue Shock Syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
Dengue fever and dengue hemorrhagic fever/dengue shock syndrome are highly infectious diseases caused by dengue virus (DV). Specific monoclonal antibodies (mAbs) against DV are vital for diagnosis, pathological studies, and passive immune therapy. In this study, purified DV serotype 2 (DV2) was used as antigen and BALB/c mice were immunized to induce specific antibodies. We established five hybridoma cell lines, called 78#, 1E7, 7F7, 8F12, and 8H1, respectively, and evaluated them by enzyme-linked immunosorbent assay, indirect immunofluorescence assay, Western blot, plaque reduction neutralization test, and suckling mice protection assay. Lines 78#, 1E7, 7F7, and 8F12 showed a neutralizing effect, and lines 78#, 1E7, 8F12, and 8H1 recognized envelope glycoprotein of DV2. Among them, lines 78# and 8F12 had stronger neutralizing ability in vitro and could protect some suckling mice from virus challenge. Our results demonstrate that immunization with purified virion is efficient for the production of specific neutralizing mAbs against DV2, and these mAbs could be useful tools for studying or treating DV infection.
引用
收藏
页码:326 / 331
页数:5
相关论文
共 50 条
  • [41] Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model
    Niu, Xuefeng
    Zhao, Lingzhai
    Qu, Linbing
    Yao, Zhipeng
    Zhan, Fan
    Yan, Qihong
    Zhang, Shengnan
    Liang, Renshan
    Chen, Peihai
    Luo, Jia
    Xu, Wei
    Lv, Huibin
    Liu, Xinglong
    Lei, Hui
    Yi, Changhua
    Li, Pingchao
    Wang, Qian
    Wang, Yang
    Yu, Lei
    Zhang, Xiaoyan
    Bryan, L. Aubrey
    Davidson, Edgar
    Doranz, J. Benjamin
    Feng, Liqiang
    Pan, Weiqi
    Zhang, Fuchun
    Chen, Ling
    EMERGING MICROBES & INFECTIONS, 2019, 8 (01) : 749 - 759
  • [42] Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity
    Huang, YH
    Chang, BI
    Lei, HY
    Liu, HS
    Liu, CC
    Wu, HL
    Yeh, TM
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 110 (01) : 35 - 40
  • [43] Generation and characterization of a rat monoclonal antibody against the RNA polymerase protein from Dengue Virus-2
    Garcia-Cordero, J.
    Carrillo-Halfon, S.
    Leon-Juarez, M.
    Romero-Ramirez, H.
    Valenzuela-Leon, P.
    Lopez-Gonzalez, M.
    Santos-Argumedo, L.
    Gutierrez-Castaneda, B.
    Gonzalez-Y-Merchand, J. A.
    Cedillo-Barron, L.
    IMMUNOLOGICAL INVESTIGATIONS, 2014, 43 (01) : 28 - 40
  • [44] Genetic basis of attenuation of Dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells
    Blaney, JE
    Johnson, DH
    Manipon, GG
    Firestone, CY
    Hanson, CT
    Murphy, BR
    Whitehead, SS
    VIROLOGY, 2002, 300 (01) : 125 - 139
  • [45] Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort
    Katzelnick, Leah C.
    Montoya, Magelda
    Gresh, Lionel
    Balmaseda, Angel
    Harris, Eva
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (03) : 728 - 733
  • [46] Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis
    Cheng, Yi-Ling
    Chao, Chiao-Hsuan
    Lai, Yen-Chung
    Hsieh, Kun-Han
    Wang, Jen-Ren
    Wan, Shu-Wen
    Huang, Hong-Jyun
    Chuang, Yung-Chun
    Chuang, Woei-Jer
    Yeh, Trai-Ming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [47] Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice
    Zheng, Xiaoyan
    Chen, Hui
    Wang, Ran
    Fan, Dongying
    Feng, Kaihao
    Gao, Na
    An, Jing
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2017, 7
  • [48] Japanese Encephalitis DNA Vaccines with Epitope Modification Reduce the Induction of Cross-Reactive Antibodies against Dengue Virus and Antibody-Dependent Enhancement of Dengue Virus Infection
    Kotaki, Tomohiro
    Nagai, Yurie
    Yamanaka, Atsushi
    Konishi, Eiji
    Kameoka, Masanori
    VACCINES, 2022, 10 (09)
  • [49] Experimental evidence for a high rate of maternal-fetal transmission of dengue virus in the presence of antibodies in immunocompromised mice
    Watanabe, Satoru
    Chan, Kitti Wing Ki
    Tan, Nicole Wei Wen
    Mahid, Maharah Binte Abdul
    Chowdhury, Avisha
    Chang, Kenneth Tou En
    Vasudevan, Subhash G.
    EBIOMEDICINE, 2022, 77
  • [50] Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus
    Pipattanaboon, Chonlatip
    Sasaki, Tadahiro
    Nishimura, Mitsuhiro
    Setthapramote, Chayanee
    Pitaksajjakul, Pannamthip
    Leaungwutiwong, Pornsawan
    Limkittikul, Kriengsak
    Puiprom, Orapim
    Sasayama, Mikiko
    Chaichana, Panjaporn
    Okabayashi, Tamaki
    Kurosu, Takeshi
    Ono, Ken-ichiro
    Ramasoota, Pongrama
    Ikuta, Kazuyoshi
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 175 - 186